Olmesartan‐induced enteropathy associated with cutaneous lesions

Olmesartan is an angiotensin II receptor antagonist which may cause severe sprue‐like enteropathy with duodenal villous atrophy. Skin lesions may be associated as reported for the first time in our case. Clinicians should be informed of this side effect and its reversibility after suspension of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammoudi, Nassim, Dior, Marie, Giraud, Vincent, Coffin, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831388/
https://www.ncbi.nlm.nih.gov/pubmed/27099732
http://dx.doi.org/10.1002/ccr3.531
_version_ 1782427063530029056
author Hammoudi, Nassim
Dior, Marie
Giraud, Vincent
Coffin, Benoit
author_facet Hammoudi, Nassim
Dior, Marie
Giraud, Vincent
Coffin, Benoit
author_sort Hammoudi, Nassim
collection PubMed
description Olmesartan is an angiotensin II receptor antagonist which may cause severe sprue‐like enteropathy with duodenal villous atrophy. Skin lesions may be associated as reported for the first time in our case. Clinicians should be informed of this side effect and its reversibility after suspension of the drug.
format Online
Article
Text
id pubmed-4831388
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48313882016-04-20 Olmesartan‐induced enteropathy associated with cutaneous lesions Hammoudi, Nassim Dior, Marie Giraud, Vincent Coffin, Benoit Clin Case Rep Case Reports Olmesartan is an angiotensin II receptor antagonist which may cause severe sprue‐like enteropathy with duodenal villous atrophy. Skin lesions may be associated as reported for the first time in our case. Clinicians should be informed of this side effect and its reversibility after suspension of the drug. John Wiley and Sons Inc. 2016-03-02 /pmc/articles/PMC4831388/ /pubmed/27099732 http://dx.doi.org/10.1002/ccr3.531 Text en © 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Hammoudi, Nassim
Dior, Marie
Giraud, Vincent
Coffin, Benoit
Olmesartan‐induced enteropathy associated with cutaneous lesions
title Olmesartan‐induced enteropathy associated with cutaneous lesions
title_full Olmesartan‐induced enteropathy associated with cutaneous lesions
title_fullStr Olmesartan‐induced enteropathy associated with cutaneous lesions
title_full_unstemmed Olmesartan‐induced enteropathy associated with cutaneous lesions
title_short Olmesartan‐induced enteropathy associated with cutaneous lesions
title_sort olmesartan‐induced enteropathy associated with cutaneous lesions
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831388/
https://www.ncbi.nlm.nih.gov/pubmed/27099732
http://dx.doi.org/10.1002/ccr3.531
work_keys_str_mv AT hammoudinassim olmesartaninducedenteropathyassociatedwithcutaneouslesions
AT diormarie olmesartaninducedenteropathyassociatedwithcutaneouslesions
AT giraudvincent olmesartaninducedenteropathyassociatedwithcutaneouslesions
AT coffinbenoit olmesartaninducedenteropathyassociatedwithcutaneouslesions

Ejemplares similares